{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=14", "query": { "condition": "Neuroendocrine Cancer", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 2740, "total_pages": 274, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T00:15:32.475Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06108479", "title": "Study of DF6215 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Solid Tumor Cancer" ], "interventions": [ { "name": "DF6215", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-11-28", "completion_date": "2025-12-04", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06108479" }, { "nct_id": "NCT01856023", "title": "HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "High Dose Interleukin-2", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clinigen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2013-05", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2023-12-05", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 12, "location_summary": "Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856023" }, { "nct_id": "NCT01078961", "title": "An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-09", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-06-08", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01078961" }, { "nct_id": "NCT04028479", "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Adenocystic Carcinoma", "Anal Cancer", "Appendix Cancer", "Brain Tumor", "Glioblastoma", "Astrocytoma", "Bile Duct Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Bone Cancer", "Synovial Sarcoma", "Chondrosarcoma", "Liposarcoma", "Sarcoma, Kaposi", "Sarcoma,Soft Tissue", "Sarcoma", "Osteosarcoma", "CNS Cancer", "Brain Stem Neoplasms", "Breast Cancer", "Cervical Cancer", "Colorectal Cancer", "Rectal Cancer", "Colon Cancer", "Esophageal Cancer", "Esophagus Cancer", "Cancer of Colon", "Pancreatic Cancer", "Cancer of Pancreas", "Testis Cancer", "Testicular Cancer", "Ureter Cancer", "Renal Cell Carcinoma", "Kidney Cancer", "Gestational Trophoblastic Tumor", "Head and Neck Neoplasms", "Parotid Tumor", "Larynx Cancer", "Tongue Cancer", "Pharynx Cancer", "Salivary Gland Cancer", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Multiple Myeloma", "Non Hodgkin Lymphoma", "Carcinoid Tumor", "Lung Cancer", "Neuroendocrine Tumors", "Mesothelioma", "Thyroid Cancer", "Parathyroid Neoplasms", "Adrenal Cancer", "Small Bowel Cancer", "Stomach Cancer", "Liver Cancer", "Hepatic Cancer", "Melanoma", "Skin Cancer", "Unknown Primary Tumors", "Uterine Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Prostate Cancer", "Vaginal Cancer", "Penile Cancer", "Vulvar Cancer", "Waldenstrom Macroglobulinemia", "Cancer, Advanced", "Thymus Cancer", "Nasopharyngeal Carcinoma", "Multiple Endocrine Neoplasia", "Pheochromocytoma", "Small Cell Carcinoma", "Pulmonary Carcinoma" ], "interventions": [ { "name": "Biomarker Testing (L)", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Treatment (T)", "type": "DRUG" }, { "name": "Patient Reported Outcomes (P)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "OTHER" ], "sponsor": "Taproot Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2021-05-05", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 2, "location_summary": "Idaho Falls, Idaho • Laredo, Texas", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028479" }, { "nct_id": "NCT02158520", "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Mucosal Melanoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-10-18", "completion_date": "2019-10-30", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 13, "location_summary": "San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158520" }, { "nct_id": "NCT00889980", "title": "Melanoma Molecular Profiling Analysis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Biospecimen banking", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 237, "start_date": "2008-05", "completion_date": "2019-07-22", "has_results": false, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889980" }, { "nct_id": "NCT03329846", "title": "An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma", "Skin Cancer" ], "interventions": [ { "name": "BMS-986205", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 20, "start_date": "2017-11-30", "completion_date": "2020-07-02", "has_results": true, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Miami Beach, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329846" }, { "nct_id": "NCT05026983", "title": "Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-12-27", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05026983" }, { "nct_id": "NCT03896503", "title": "Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma", "Extrapulmonary Small Cell Neuroendocrine Carcinoma", "Limited Stage Lung Small Cell Carcinoma", "Platinum-Resistant Lung Small Cell Carcinoma", "Platinum-Sensitive Lung Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2019-12-30", "completion_date": "2027-05-13", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 33, "location_summary": "Los Angeles, California • Newport Beach, California • Sacramento, California + 26 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896503" }, { "nct_id": "NCT02054520", "title": "Immunotherapy Study for Patients With Stage IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "HyperAcute®-Melanoma (HAM) Immunotherapy", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2014-06", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-10-22T00:15:32.475Z", "location_count": 5, "location_summary": "Niles, Illinois • Iowa City, Iowa • Westwood, Kansas + 2 more", "locations": [ { "city": "Niles", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02054520" } ] }